Pivotal Study of Iodine I 131 Tositumomab for Chemotherapy-refractory Low-grade or Transformed Low-grade B-cell Non-Hodgkin's Lymphoma
NCT00989664
·
clinicaltrials.gov ↗
PHASE2
Phase
COMPLETED
Status
60
Enrollment
INDUSTRY
Sponsor class
Conditions
Lymphoma, Non-Hodgkin
Interventions
BIOLOGICAL:
Tositumomab and Iodine I 131 Tositumomab
Sponsor
GlaxoSmithKline